Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Pembrolizumab benefits some patients with advanced cervical cancer

Key clinical point: Pembrolizumab is a reasonable option for patients with advanced cervical cancer, especially those positive for PD-L1.

Major finding: Three PD-L1 patients had a complete response and nine had a partial response.

Study details: The prospective open-label study comprised 98 subjects.

Disclosures: Merck & Co. sponsored the study.

Citation:

Chung HC et al. J Clin Oncol. 2019 April 3. doi: 10.1200/JCO.18.01265.